Ryan Pekson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Ryan Pekson has a total of 332 co-authors. Here are the top co-authors by number of shared publications:
- Sandra E. Reznik
Department of Pharmaceutical Sciences, St. John's University, Jamaica, NY, United States; Departments of Pathology and Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine, Bronx, NY, United States
7 shared publications Charles R. Ashby
Department of Pharmaceutical Sciences, St. John's University, Queens, NY, USA
5 shared publicationsSruthi Sundaram
Toxicon, Bedford, MA
4 shared publications- Swapna Munnangi
Department of Surgery, Nassau University Medical Center, East Meadow, NY, USA
4 shared publications - Richard N. Kitsis
Department of Medicine, Albert Einstein College of Medicine, Bronx, USA
3 shared publications Samir Gorasiya
Blubird Bio Inc, Cambridge, MA, UK
3 shared publications
Latest Publications
- Open Access
- 14 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 29861
N,N-Diethylacetamide and N,N-Dipropylacetamide inhibit the NF-kB pathway in in vitro, ex vivo and in vivo models of inflammation-induced preterm birth
Preterm birth (PTB) occurs in 10% of births worldwide and remains the leading cause of neonatal morbidity and mortality. Previously, we reported that N, N-dimethylacetamide (DMA) and N, N-dimethylformamide (DMF) prevent inflammation-induced PTB in a murine model and inhibit the NF-κB inflammatory pathway. Using in vitro and ex vivo models, we show here that two DMA analogs, N,N-diethylaceatmide (DEA) and N, N-dipropylacetamide (DPA), attenuate LPS-stimulated increased secretion of tumor necrosis factor (TNF)-α, IL-6, IL-1, GM-CSF, MCP-1 and IL-10 from RAW 264.7 cells; IL-6, IL-8 and MCP-1 from HTR-8/SVneo cells; and TNF-α, IL-6, GM-CSF, IL-8, MCP-1 and IL-10 from human placental explants. In addition, both analogs inhibited LPS induced up-regulation of nitric oxide (NO) secretion and inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells. Further, both analogs, at 10 mM, inhibited LPS-induced degradation of IkB-⍺ in RAW 264.7 cells, leading to inhibition of the NF-kB pathway. We also found that both analogs inhibited LPS-stimulated NF-kB transcriptional activity but did not affect AP-1 or C/EBP activity. However, neither analog had any effect on the expression of native or phosphorylated forms of JNK1, ERK1/2 and p-38 MAPK. Finally, in a well-established in vivo model of preterm birth, DEA, at 750 mg/kg, prevented preterm birth for at least 24 h. DEA and DPA have potential as novel therapeutic agents for the prevention of inflammation-induced preterm birth and other inflammatory disorders.
- 14 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 29861
Open AccessN,N-Diethylacetamide and N,N-Dipropylacetamide inhibit the NF-kB pathway in in vitro, ex vivo and in vivo models of inflammation-induced preterm birth
Preterm birth (PTB) occurs in 10% of births worldwide and remains the leading cause of neonatal morbidity and mortality. Previously, we reported that N, N-dimethylacetamide (DMA) and N, N-dimethylformamide (DMF) prevent inflammation-induced PTB in a murine model and inhibit the NF-κB inflammatory pathway. Using in vitro and ex vivo models, we show here that two DMA analogs, N,N-diethylaceatmide (DEA) and N, N-dipropylacetamide (DPA), attenuate LPS-stimulated increased secretion of tumor necrosis factor (TNF)-α, IL-6, IL-1, GM-CSF, MCP-1 and IL-10 from RAW 264.7 cells; IL-6, IL-8 and MCP-1 from HTR-8/SVneo cells; and TNF-α, IL-6, GM-CSF, IL-8, MCP-1 and IL-10 from human placental explants. In addition, both analogs inhibited LPS induced up-regulation of nitric oxide (NO) secretion and inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells. Further, both analogs, at 10 mM, inhibited LPS-induced degradation of IkB-⍺ in RAW 264.7 cells, leading to inhibition of the NF-kB pathway. We also found that both analogs inhibited LPS-stimulated NF-kB transcriptional activity but did not affect AP-1 or C/EBP activity. However, neither analog had any effect on the expression of native or phosphorylated forms of JNK1, ERK1/2 and p-38 MAPK. Finally, in a well-established in vivo model of preterm birth, DEA, at 750 mg/kg, prevented preterm birth for at least 24 h. DEA and DPA have potential as novel therapeutic agents for the prevention of inflammation-induced preterm birth and other inflammatory disorders.
- Open Access
- 4 March 2025
- Published by Springer Nature in BMC Medical Education
- Vol. 25 (1) , 1-8
GPT-4 generated answer rationales to multiple choice assessment questions in undergraduate medical education
Background: Pre-clerkship medical students benefit from practice questions that provide rationales for answer choices. Creating these rationales is a time-intensive endeavor. Therefore, not all practice multiple choice questions (MCQ) have corresponding explanations to aid learning. The authors examined artificial intelligence’s (AI) potential to create high-quality answer rationales for clinical vignette-style MCQs. Methods: The authors conducted a single-center pre-post intervention survey study in August 2023 assessing 8 pre-clerkship course director (CD) attitudes towards GPT-4 generated answer rationales to clinical vignette style MCQs. Ten MCQs from each course’s question bank were selected and input into GPT-4 with instructions to select the best answer and generate rationales for each answer choice. CDs were provided their unmodified GPT-4 interactions to assess the accuracy, clarity, appropriateness, and likelihood of implementation of the rationales. CDs were asked about time spent reviewing and making necessary modifications, satisfaction, and receptiveness in using GPT-4 for this purpose. Results: GPT-4 correctly answered 75/80 (93.8%) questions on the first attempt. CDs were receptive to using GPT-4 for rationale generation and all were satisfied with the generated rationales. CDs determined that the majority of rationales were very accurate (77.5%), very clear (83.8%) and very appropriate (93.8%). Most rationales could be implemented with little or no modification (88.3%). All CDs would implement AI-generated answer rationales with CD editorial insights. Most CDs (75%) took ≤ 4 min to review a set of generated rationales for a question. Conclusion: GPT-4 is an acceptable and feasible tool for generating accurate, clear and appropriate answer rationales for MCQs in medical education. Future studies should examine students’ feedback to generated rationales and further explore generating rationales for question with media. The authors plan to explore the implementation of this technological application at their medical school, including logistics and training to create a streamlined process that benefits both learners and educators. Clinical trial: Not applicable; not a clinical trial.
- 4 March 2025
- Published by Springer Nature in BMC Medical Education
- Vol. 25 (1) , 1-8
Open AccessGPT-4 generated answer rationales to multiple choice assessment questions in undergraduate medical education
Background: Pre-clerkship medical students benefit from practice questions that provide rationales for answer choices. Creating these rationales is a time-intensive endeavor. Therefore, not all practice multiple choice questions (MCQ) have corresponding explanations to aid learning. The authors examined artificial intelligence’s (AI) potential to create high-quality answer rationales for clinical vignette-style MCQs. Methods: The authors conducted a single-center pre-post intervention survey study in August 2023 assessing 8 pre-clerkship course director (CD) attitudes towards GPT-4 generated answer rationales to clinical vignette style MCQs. Ten MCQs from each course’s question bank were selected and input into GPT-4 with instructions to select the best answer and generate rationales for each answer choice. CDs were provided their unmodified GPT-4 interactions to assess the accuracy, clarity, appropriateness, and likelihood of implementation of the rationales. CDs were asked about time spent reviewing and making necessary modifications, satisfaction, and receptiveness in using GPT-4 for this purpose. Results: GPT-4 correctly answered 75/80 (93.8%) questions on the first attempt. CDs were receptive to using GPT-4 for rationale generation and all were satisfied with the generated rationales. CDs determined that the majority of rationales were very accurate (77.5%), very clear (83.8%) and very appropriate (93.8%). Most rationales could be implemented with little or no modification (88.3%). All CDs would implement AI-generated answer rationales with CD editorial insights. Most CDs (75%) took ≤ 4 min to review a set of generated rationales for a question. Conclusion: GPT-4 is an acceptable and feasible tool for generating accurate, clear and appropriate answer rationales for MCQs in medical education. Future studies should examine students’ feedback to generated rationales and further explore generating rationales for question with media. The authors plan to explore the implementation of this technological application at their medical school, including logistics and training to create a streamlined process that benefits both learners and educators. Clinical trial: Not applicable; not a clinical trial.
- Open Access
- 13 December 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (51)
The mitochondrial ATP synthase is a negative regulator of the mitochondrial permeability transition pore
The mitochondrial permeability transition pore (mPTP) is a channel in the inner mitochondrial membrane whose sustained opening in response to elevated mitochondrial matrix Ca 2+ concentrations triggers necrotic cell death. The molecular identity of mPTP is unknown. One proposed candidate is the mitochondrial ATP synthase, whose canonical function is to generate most ATP in multicellular organisms. Here, we present mitochondrial, cellular, and in vivo evidence that, rather than serving as mPTP, the mitochondrial ATP synthase inhibits this pore. Our studies confirm previous work showing persistence of mPTP in HAP1 cell lines lacking an assembled mitochondrial ATP synthase. Unexpectedly, however, we observe that Ca 2+ -induced pore opening is markedly sensitized by loss of the mitochondrial ATP synthase. Further, mPTP opening in cells lacking the mitochondrial ATP synthase is desensitized by pharmacological inhibition and genetic depletion of the mitochondrial cis-trans prolyl isomerase cyclophilin D as in wild-type cells, indicating that cyclophilin D can modulate mPTP through substrates other than subunits in the assembled mitochondrial ATP synthase. Mitoplast patch clamping studies showed that mPTP channel conductance was unaffected by loss of the mitochondrial ATP synthase but still blocked by cyclophilin D inhibition. Cardiac mitochondria from mice whose heart muscle cells we engineered deficient in the mitochondrial ATP synthase also demonstrate sensitization of Ca 2+ -induced mPTP opening and desensitization by cyclophilin D inhibition. Further, these mice exhibit strikingly larger myocardial infarctions when challenged with ischemia/reperfusion in vivo. We conclude that the mitochondrial ATP synthase does not function as mPTP and instead negatively regulates this pore.
- 13 December 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (51)
Open AccessThe mitochondrial ATP synthase is a negative regulator of the mitochondrial permeability transition pore
The mitochondrial permeability transition pore (mPTP) is a channel in the inner mitochondrial membrane whose sustained opening in response to elevated mitochondrial matrix Ca 2+ concentrations triggers necrotic cell death. The molecular identity of mPTP is unknown. One proposed candidate is the mitochondrial ATP synthase, whose canonical function is to generate most ATP in multicellular organisms. Here, we present mitochondrial, cellular, and in vivo evidence that, rather than serving as mPTP, the mitochondrial ATP synthase inhibits this pore. Our studies confirm previous work showing persistence of mPTP in HAP1 cell lines lacking an assembled mitochondrial ATP synthase. Unexpectedly, however, we observe that Ca 2+ -induced pore opening is markedly sensitized by loss of the mitochondrial ATP synthase. Further, mPTP opening in cells lacking the mitochondrial ATP synthase is desensitized by pharmacological inhibition and genetic depletion of the mitochondrial cis-trans prolyl isomerase cyclophilin D as in wild-type cells, indicating that cyclophilin D can modulate mPTP through substrates other than subunits in the assembled mitochondrial ATP synthase. Mitoplast patch clamping studies showed that mPTP channel conductance was unaffected by loss of the mitochondrial ATP synthase but still blocked by cyclophilin D inhibition. Cardiac mitochondria from mice whose heart muscle cells we engineered deficient in the mitochondrial ATP synthase also demonstrate sensitization of Ca 2+ -induced mPTP opening and desensitization by cyclophilin D inhibition. Further, these mice exhibit strikingly larger myocardial infarctions when challenged with ischemia/reperfusion in vivo. We conclude that the mitochondrial ATP synthase does not function as mPTP and instead negatively regulates this pore.
- Open Access
- 7 July 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-20
Modulating mitofusins to control mitochondrial function and signaling
Mitofusins reside on the outer mitochondrial membrane and regulate mitochondrial fusion, a physiological process that impacts diverse cellular processes. Mitofusins are activated by conformational changes and subsequently oligomerize to enable mitochondrial fusion. Here, we identify small molecules that directly increase or inhibit mitofusins activity by modulating mitofusin conformations and oligomerization. We use these small molecules to better understand the role of mitofusins activity in mitochondrial fusion, function, and signaling. We find that mitofusin activation increases, whereas mitofusin inhibition decreases mitochondrial fusion and functionality. Remarkably, mitofusin inhibition also induces minority mitochondrial outer membrane permeabilization followed by sub-lethal caspase-3/7 activation, which in turn induces DNA damage and upregulates DNA damage response genes. In this context, apoptotic death induced by a second mitochondria-derived activator of caspases (SMAC) mimetic is potentiated by mitofusin inhibition. These data provide mechanistic insights into the function and regulation of mitofusins as well as small molecules to pharmacologically target mitofusins.
- 7 July 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-20
Open AccessModulating mitofusins to control mitochondrial function and signaling
Mitofusins reside on the outer mitochondrial membrane and regulate mitochondrial fusion, a physiological process that impacts diverse cellular processes. Mitofusins are activated by conformational changes and subsequently oligomerize to enable mitochondrial fusion. Here, we identify small molecules that directly increase or inhibit mitofusins activity by modulating mitofusin conformations and oligomerization. We use these small molecules to better understand the role of mitofusins activity in mitochondrial fusion, function, and signaling. We find that mitofusin activation increases, whereas mitofusin inhibition decreases mitochondrial fusion and functionality. Remarkably, mitofusin inhibition also induces minority mitochondrial outer membrane permeabilization followed by sub-lethal caspase-3/7 activation, which in turn induces DNA damage and upregulates DNA damage response genes. In this context, apoptotic death induced by a second mitochondria-derived activator of caspases (SMAC) mimetic is potentiated by mitofusin inhibition. These data provide mechanistic insights into the function and regulation of mitofusins as well as small molecules to pharmacologically target mitofusins.
- 29 March 2022
- Published by Springer Nature in Reproductive Sciences
- Vol. 29 (10) , 2894-2907
N,N-Dimethylformamide Delays LPS-Induced Preterm Birth in a Murine Model by Suppressing the Inflammatory Response
Preterm birth accounts for the majority of perinatal mortality worldwide, and there remains no FDA-approved drug to prevent it. Recently, we discovered that the common drug excipient, N,N-dimethylacetamide (DMA), delays inflammation-induced preterm birth in mice by inhibiting NF-κB. Since we reported this finding, it has come to light that a group of widely used, structurally related aprotic solvents, including DMA, N-methyl-2-pyrrolidone (NMP) and dimethylformamide (DMF), have anti-inflammatory efficacy. We show here that DMF suppresses LPS-induced TNFα secretion from RAW 264.7 cells and IL-6 and IL-8 secretion from HTR-8 cells at concentrations that do not significantly affect cell viability. Like DMA, DMF protects IκBα from degradation and prevents the p65 subunit of NF-κB from translocating to the nucleus. In vivo, DMF decreases LPS-induced inflammatory cell infiltration and expression of TNFα and IL-6 in the placental labyrinth, all to near baseline levels. Finally, DMF decreases the rate of preterm birth in LPS-induced pregnant mice (P<.0001) and the rate at which pups are spontaneously aborted (P<.0001). In summary, DMF, a widely used solvent structurally related to DMA and NMP, delays LPS-induced preterm birth in a murine model without overt toxic effects. Re-purposing the DMA/DMF/NMP family of small molecules as anti-inflammatory drugs is a promising new approach to delaying or reducing the incidence of inflammation-induced preterm birth and potentially attenuating other inflammatory disorders as well.
- 29 March 2022
- Published by Springer Nature in Reproductive Sciences
- Vol. 29 (10) , 2894-2907
N,N-Dimethylformamide Delays LPS-Induced Preterm Birth in a Murine Model by Suppressing the Inflammatory Response
Preterm birth accounts for the majority of perinatal mortality worldwide, and there remains no FDA-approved drug to prevent it. Recently, we discovered that the common drug excipient, N,N-dimethylacetamide (DMA), delays inflammation-induced preterm birth in mice by inhibiting NF-κB. Since we reported this finding, it has come to light that a group of widely used, structurally related aprotic solvents, including DMA, N-methyl-2-pyrrolidone (NMP) and dimethylformamide (DMF), have anti-inflammatory efficacy. We show here that DMF suppresses LPS-induced TNFα secretion from RAW 264.7 cells and IL-6 and IL-8 secretion from HTR-8 cells at concentrations that do not significantly affect cell viability. Like DMA, DMF protects IκBα from degradation and prevents the p65 subunit of NF-κB from translocating to the nucleus. In vivo, DMF decreases LPS-induced inflammatory cell infiltration and expression of TNFα and IL-6 in the placental labyrinth, all to near baseline levels. Finally, DMF decreases the rate of preterm birth in LPS-induced pregnant mice (P<.0001) and the rate at which pups are spontaneously aborted (P<.0001). In summary, DMF, a widely used solvent structurally related to DMA and NMP, delays LPS-induced preterm birth in a murine model without overt toxic effects. Re-purposing the DMA/DMF/NMP family of small molecules as anti-inflammatory drugs is a promising new approach to delaying or reducing the incidence of inflammation-induced preterm birth and potentially attenuating other inflammatory disorders as well.
- 1 November 2019
- Published by Elsevier in The American Journal of Pathology
- Vol. 189 (11) , 2246-2257
N-Acetylcysteine Resolves Placental Inflammatory-Vasculopathic Changes in Mice Consuming a High-Fat Diet
- 1 November 2019
- Published by Elsevier in The American Journal of Pathology
- Vol. 189 (11) , 2246-2257
N-Acetylcysteine Resolves Placental Inflammatory-Vasculopathic Changes in Mice Consuming a High-Fat Diet
- 18 May 2018
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 24 (9) , 989-992
Repurposing N,N-Dimethylacetamide (DMA), a Pharmaceutical Excipient, as a Prototype Novel Anti-inflammatory Agent for the Prevention and/or Treatment of Preterm Birth
Background: Preterm birth (PTB), or birth that occurs before 37 weeks of gestation, accounts for the majority of perinatal morbidity and mortality. As of 2016, PTB has an occurrence rate of 9.6% in the United States and accounts for up to 18 percent of births worldwide. Inflammation has been identified as the most common cause of PTB, but effective pharmacotherapy has yet to be developed to prevent inflammation driven PTB. Our group has discovered that N,N-dimethylacetamide (DMA), a readily available solvent commonly used as a pharmaceutical excipient, rescues lipopolysaccharide (LPS)-induced timed pregnant mice from PTB. Methods: We have used in vivo, ex vivo and in vitro approaches to investigate this compound further. Results: Interestingly, we found that DMA suppresses cytokine secretion by inhibiting nuclear factor-kappa B (NF-κB). In ongoing work in this exciting line of investigation, we are currently investigating structural analogs of DMA, some of them novel, to optimize this approach focused on the inflammation associated with PTB. Conclusion: Successful development of pharmacotherapy for the prevention of PTB rests upon the pursuit of multiple strategies to solve this important clinical challenge.
- 18 May 2018
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 24 (9) , 989-992
Repurposing N,N-Dimethylacetamide (DMA), a Pharmaceutical Excipient, as a Prototype Novel Anti-inflammatory Agent for the Prevention and/or Treatment of Preterm Birth
Background: Preterm birth (PTB), or birth that occurs before 37 weeks of gestation, accounts for the majority of perinatal morbidity and mortality. As of 2016, PTB has an occurrence rate of 9.6% in the United States and accounts for up to 18 percent of births worldwide. Inflammation has been identified as the most common cause of PTB, but effective pharmacotherapy has yet to be developed to prevent inflammation driven PTB. Our group has discovered that N,N-dimethylacetamide (DMA), a readily available solvent commonly used as a pharmaceutical excipient, rescues lipopolysaccharide (LPS)-induced timed pregnant mice from PTB. Methods: We have used in vivo, ex vivo and in vitro approaches to investigate this compound further. Results: Interestingly, we found that DMA suppresses cytokine secretion by inhibiting nuclear factor-kappa B (NF-κB). In ongoing work in this exciting line of investigation, we are currently investigating structural analogs of DMA, some of them novel, to optimize this approach focused on the inflammation associated with PTB. Conclusion: Successful development of pharmacotherapy for the prevention of PTB rests upon the pursuit of multiple strategies to solve this important clinical challenge.
- Open Access
- 1 April 2017
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 2 (2) , 118-121
Troponin Release Following Brief Myocardial Ischemia
- 1 April 2017
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 2 (2) , 118-121
Open AccessTroponin Release Following Brief Myocardial Ischemia
- Open Access
- 1 January 2016
- Published by Springer Nature in Molecular Medicine
- Vol. 22 (1) , 747-758
N,N-Dimethylacetamide Significantly Attenuates LPS- and TNFα-Induced Proinflammatory Responses Via Inhibition of the Nuclear Factor Kappa B Pathway
Previously, we have shown that N,N-dimethylacetamide (DMA) prevents inflammation-induced preterm birth in a murine model, inhibits lipopolysaccharide (LPS)-induced increases in placental proinflammatory cytokines and upregulates the antiinflammatory cytokine interleukin-10 (IL-10). However, DMA’s mechanism of action remains to be elucidated. In the current study, we investigate how DMA produces its antiinflammatory effect. Using in vitro and ex vivo models, we show that DMA suppresses secretion of proinflammatory cytokines in lipopolysaccharide (LPS)-induced RAW 264.7 cells, TNFα-challenged JEG-3 cells and LPS-stimulated human placental explants. DMA significantly attenuated secretion of TNFα, IL-6, IL-10 and granulocyte macrophage colony stimulating factor (GM-CSF) from LPS-stimulated RAW 264.7 cells; IL-6 secretion from TNFα-stimulated JEG-3 cells; and TNFα, IL-6, IL-10, GM-CSF and Interleukin-8 (IL-8) from LPS-stimulated human placental explants. We further investigated whether DMA’s effect on cytokine expression involves the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein kinase (MAPK) pathways. DMA (10 mM) significantly inhibited degradation of nuclear factor of kappa light polypeptide gene enhancer in B cell inhibitor a (IκBα) in LPS-stimulated RAW 264.7 cells, but there was no significant change in the expression of phosphorylated or native forms of downstream proteins in the MAPK pathway. In addition, DMA significantly attenuated luciferase activity in cells co-transfected with NF-κB-Luc reporter plasmid, but not with AP-1-Luc or CEBP-Luc reporters. Overall, our findings suggest that the antiinflammatory activity of DMA is mediated by inhibition of the NF-κB pathway via decreased IκBa degradation.
- 1 January 2016
- Published by Springer Nature in Molecular Medicine
- Vol. 22 (1) , 747-758
Open AccessN,N-Dimethylacetamide Significantly Attenuates LPS- and TNFα-Induced Proinflammatory Responses Via Inhibition of the Nuclear Factor Kappa B Pathway
Previously, we have shown that N,N-dimethylacetamide (DMA) prevents inflammation-induced preterm birth in a murine model, inhibits lipopolysaccharide (LPS)-induced increases in placental proinflammatory cytokines and upregulates the antiinflammatory cytokine interleukin-10 (IL-10). However, DMA’s mechanism of action remains to be elucidated. In the current study, we investigate how DMA produces its antiinflammatory effect. Using in vitro and ex vivo models, we show that DMA suppresses secretion of proinflammatory cytokines in lipopolysaccharide (LPS)-induced RAW 264.7 cells, TNFα-challenged JEG-3 cells and LPS-stimulated human placental explants. DMA significantly attenuated secretion of TNFα, IL-6, IL-10 and granulocyte macrophage colony stimulating factor (GM-CSF) from LPS-stimulated RAW 264.7 cells; IL-6 secretion from TNFα-stimulated JEG-3 cells; and TNFα, IL-6, IL-10, GM-CSF and Interleukin-8 (IL-8) from LPS-stimulated human placental explants. We further investigated whether DMA’s effect on cytokine expression involves the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein kinase (MAPK) pathways. DMA (10 mM) significantly inhibited degradation of nuclear factor of kappa light polypeptide gene enhancer in B cell inhibitor a (IκBα) in LPS-stimulated RAW 264.7 cells, but there was no significant change in the expression of phosphorylated or native forms of downstream proteins in the MAPK pathway. In addition, DMA significantly attenuated luciferase activity in cells co-transfected with NF-κB-Luc reporter plasmid, but not with AP-1-Luc or CEBP-Luc reporters. Overall, our findings suggest that the antiinflammatory activity of DMA is mediated by inhibition of the NF-κB pathway via decreased IκBa degradation.
- Open Access
- 1 March 2015
- Published by Elsevier in The American Journal of Pathology
- Vol. 185 (3) , 862-869
Inhibition of Sphingosine Kinase Prevents Lipopolysaccharide-Induced Preterm Birth and Suppresses Proinflammatory Responses in a Murine Model
- 1 March 2015
- Published by Elsevier in The American Journal of Pathology
- Vol. 185 (3) , 862-869
Open AccessInhibition of Sphingosine Kinase Prevents Lipopolysaccharide-Induced Preterm Birth and Suppresses Proinflammatory Responses in a Murine Model